HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN priorities

This article was originally published in The Rose Sheet

Executive Summary

FDA requests public comment on the Center for Safety & Applied Nutrition's program priorities for 2000 in an announcement published in the Federal Register Sept. 1. Comments are due Sept. 30. CFSAN's 1999 "A" priority list includes reinstating the Voluntary Cosmetic Registration Program and completing the safety assessment and review of alpha hydroxy acids and diethanolamine (1"The Rose Sheet" Feb. 1, p. 7). Among goals on the Office of Cosmetics & Colors' priority "B" list in 1999 is issuing a report on adverse reactions (2"The Rose Sheet" Feb. 8, p. 6)

FDA requests public comment on the Center for Safety & Applied Nutrition's program priorities for 2000 in an announcement published in the Federal Register Sept. 1. Comments are due Sept. 30. CFSAN's 1999 "A" priority list includes reinstating the Voluntary Cosmetic Registration Program and completing the safety assessment and review of alpha hydroxy acids and diethanolamine (1 (Also see "CFSAN Priorities List For 1999 Includes Four Cosmetics Issues" - HBW Insight, 1 Feb, 1999.)). Among goals on the Office of Cosmetics & Colors' priority "B" list in 1999 is issuing a report on adverse reactions (2 (Also see "FDA "B" List For Cosmetics Priorities Includes Adverse Event Monitoring" - HBW Insight, 8 Feb, 1999.)).

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel